{"id":31531,"date":"2025-03-03T09:32:39","date_gmt":"2025-03-03T08:32:39","guid":{"rendered":"https:\/\/ggba.swiss\/?p=31531"},"modified":"2025-03-03T09:33:24","modified_gmt":"2025-03-03T08:33:24","slug":"atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/","title":{"rendered":"ATANIS Biotech secures USD 2 million for its FAST-PASE allergy test"},"content":{"rendered":"\n<p>Bern-based biotechnology company <a href=\"https:\/\/www.atanis-biotech.com\/\">ATANIS Biotech<\/a>, specializing in functional allergy diagnostics, has been awarded Phase 2 of the <a href=\"https:\/\/www.foodallergy.org\/research-innovation\/accelerating-innovation\/pioneering-advances-diagnosis\/fare-innovation-award\">FARE Innovation Award Diagnostic Challenge<\/a>. The company\u2019s FAST-PASE allergy test, a functional ex vivo mast cell activation assay, was selected by FARE (Food Allergy Research &amp; Education) after rigorous scientific evaluation, securing USD 2 million in funding to accelerate commercialization and clinical adoption.<\/p>\n\n\n\n<p>Founded as a University of Bern spin-off, ATANIS is focused on revolutionizing allergy testing by replacing outdated, risk-laden in vivo methods with its proprietary FAST-PASE technology. This innovative assay utilizes engineered mast cells that replicate natural allergic reactions when exposed to allergens, offering a safer, scalable, and highly accurate alternative to traditional oral food challenges (OFCs). In a recent clinical utility study, FAST-PASE demonstrated over 95% accuracy in diagnosing peanut allergies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Strong clinical validation and growing industry recognition<\/h4>\n\n\n\n<p>FARE CEO, Dr. Sung Poblete, emphasized the award\u2019s significance: \u201cWhile OFCs play a critical role in developing new treatments in research settings and diagnosing food allergy in clinical settings, they involve supervised ingestion of a suspected allergen and therefore carry some risk of anaphylaxis for the patient. We are pleased to announce ATANIS Biotech as the newest winner of the Innovation Award Diagnostic Challenge.\u201d<\/p>\n\n\n\n<p>The funding will support FAST-PASE\u2019s development across multiple allergy indications, with ATANIS collaborating with leading global allergy experts, including Mount Sinai, Baylor College of Medicine, SickKids Toronto, and the University of Bern.<\/p>\n\n\n\n<p>ATANIS CEO, Prof. Jean-Pierre Kinet, highlighted the strategic impact of this partnership: \u201cI am delighted to partner with such a highly reputed organization as FARE and such high-caliber scientists and physicians in pursuing our mission of bringing safer tests to allergy patients throughout the world.\u201d<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"The Startup Ecosystem in the Canton of Bern\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/d6YxuxfFipc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Bernese start-up ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2 million to advance its FAST-PASE allergy test.<\/p>\n","protected":false},"author":6,"featured_media":31532,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,928,890],"class_list":["post-31531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-food-beverages","tag-healthcare"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ATANIS Biotech secures USD 2 million for its allergy test | GGBa<\/title>\n<meta name=\"description\" content=\"ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2M to advance its FAST-PASE allergy test.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATANIS Biotech secures USD 2 million for its allergy test | GGBa\" \/>\n<meta property=\"og:description\" content=\"ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2M to advance its FAST-PASE allergy test.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T08:32:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T08:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"ATANIS Biotech secures USD 2 million for its FAST-PASE allergy test\",\"datePublished\":\"2025-03-03T08:32:39+00:00\",\"dateModified\":\"2025-03-03T08:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\"},\"wordCount\":297,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Food &amp; Beverages\",\"Healthcare\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\",\"url\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\",\"name\":\"ATANIS Biotech secures USD 2 million for its allergy test | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg\",\"datePublished\":\"2025-03-03T08:32:39+00:00\",\"dateModified\":\"2025-03-03T08:33:24+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2M to advance its FAST-PASE allergy test.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"ATANIS Biotech is revolutionizing allergy diagnostics with its highly accurate, functional FAST-PASE test, offering a safer alternative to oral food challenges. | \u00a9 ATANIS Biotech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATANIS Biotech secures USD 2 million for its FAST-PASE allergy test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATANIS Biotech secures USD 2 million for its allergy test | GGBa","description":"ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2M to advance its FAST-PASE allergy test.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/","og_locale":"en_US","og_type":"article","og_title":"ATANIS Biotech secures USD 2 million for its allergy test | GGBa","og_description":"ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2M to advance its FAST-PASE allergy test.","og_url":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-03-03T08:32:39+00:00","article_modified_time":"2025-03-03T08:33:24+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"ATANIS Biotech secures USD 2 million for its FAST-PASE allergy test","datePublished":"2025-03-03T08:32:39+00:00","dateModified":"2025-03-03T08:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/"},"wordCount":297,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg","keywords":["Biotech","Financing","Food &amp; Beverages","Healthcare"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/","url":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/","name":"ATANIS Biotech secures USD 2 million for its allergy test | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg","datePublished":"2025-03-03T08:32:39+00:00","dateModified":"2025-03-03T08:33:24+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2M to advance its FAST-PASE allergy test.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/03\/Atanis-Biotech-USD-2-million-1180x811-1.jpeg","width":1180,"height":811,"caption":"ATANIS Biotech is revolutionizing allergy diagnostics with its highly accurate, functional FAST-PASE test, offering a safer alternative to oral food challenges. | \u00a9 ATANIS Biotech"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/atanis-biotech-secures-usd-2-million-for-its-fast-pase-allergy-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"ATANIS Biotech secures USD 2 million for its FAST-PASE allergy test"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/31531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=31531"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/31531\/revisions"}],"predecessor-version":[{"id":31536,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/31531\/revisions\/31536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/31532"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=31531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=31531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=31531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}